Liu B, Azeem RM, Xu B, Yang YL, Zhang RR, Hu MJ, Z. Evaluation of immune protective efficacy of recombinant adenovirus vector vaccine containing RBS of influenza virus subtype H1N1. Microb Pathog. 2026 Feb 17:108383
The current seasonal influenza vaccine is only 20%-60% effective on average, and its protective effect lasts only 6-8 months. Additionally, some viruses are prone to antigenic drift, which prevents the vaccine from being fully effective. Furthermore, due to antigenic drift, they are unable to effectively address the threat of pandemics, continuing to pose a threat to global health. There is an urgent need to develop vaccine strategies that go beyond traditional vaccines. The human adenovirus type 5 (Ad5) vector is biologically safe and capable of inducing strong systemic and mucosal immune responses. Currently, the Ad5 vector is widely utilized in vaccine development against various pathogens. Here, we developed and evaluated an adenovirus-based influenza vaccine (rAd5-GFP-RBS). This vaccine focuses on the receptor-binding site (RBS) of hemagglutinin. The vaccine was delivered intranasally to C57BL/6J mice and induced robust systemic and mucosal immune responses, evidenced by significantly higher IgG levels in serum and bronchoalveolar lavage fluid. Notably, the IgG antibody titer in the alveolar lavage fluid of the rAd5-GFP-RBS group was significantly higher than that in the PBS group (***p<0.001). Following H1N1 PR8 challenge, vaccinated mice exhibited significantly enhanced survival, significantly reduced weight loss, and decreased lung pathology compared to controls. Histopathology and immunohistochemistry confirmed lower viral antigen levels in vaccinated mice. Measured influenza-specific antibodies demonstrated strong immune response, highlighting the vaccine´s potential for excellent protective immunity. These findings support rAd5-GFP-RBS as promising candidate for influenza protection, providing a platform for rapid vaccine development against emerging strains. Further optimization could improve vaccine durability and efficacy.
See Also:
Latest articles in those days:
- The evolution and transmission dynamics of H3N2 influenza virus identified in a respiratory disease outbreak in companion dogs in Alabama, USA 6 hours ago
- Structural and functional characterization of hemagglutinin E190D and Q226H minor variants in human H5N1 A/British Columbia/PHL-2032/2024 6 hours ago
- Spatial risk factors associated with outbreaks of highly pathogenic avian influenza in Pennsylvania’s commercial poultry farms 6 hours ago
- [preprint]H9N2 avian influenza virus in Bangladesh: three genetically distinct co-circulating subgroups retain a largely conserved antigenic phenotype 6 hours ago
- [preprint]Endogenous serine proteases in MDCK sublines support trypsin-independent influenza A virus replication 6 hours ago
[Go Top] [Close Window]


